Adults with opioid use disorder who receive a higher daily dose of the opioid addiction treatment medication buprenorphine may have a lower risk of subsequent emergency department visits or use of inpatient services related to behavioral health (such as for mental health and substance use disorders) than adults receiving the recommended dose, according to an analysis funded by the National Institutes of Health (NIH).
Diffusion Pharma’s stockholders support merger with EIP Pharma – Pharmaceutical Technology
Diffusion Pharma’s stockholders have agreed to its merger with EIP Pharma, creating a combined company focused on neurodegenerative disorders. Image Credit: Shutterstock / LightField Studios
August 16, 2023